NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/19/2026
Back to search
Official data from USPTO
MABQUEST THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
05/19/2026
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
07/29/2025
Registration date
05/19/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/19/2026
Last transaction
05/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
CH
Examiner
MCDORMAN, ROGER THOMAS
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a trefoil-like figure formed by a canted red equilateral triangle with a red droplet shape extending from each corner thereof, centered above the wording "MABQUEST THERAPEUTICS" in gray type.
Holders and representatives
Holders
MabQuest SA
Representatives
Andrea L. Hintz Resonate IP, LLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemicalbiological and biotechnological preparations for use in industry and science other than for medical or veterinary use; chemicalbiological and biotechnological preparationsin particular polypeptides and proteins for development or manufacture of reagents for use in industry and science; biological preparationsin particular polypeptides or proteins for use in laboratories and for non-medical diagnosis and analysis in industry and science; chemical and biochemical substances being additives for use in the manufacture of pharmaceuticals; chemical and biochemical substances for use in the manufacture of pharmaceuticals for treating cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; stem cells for research purposes; stem cells for scientific use; cultures of microorganisms other than for medical and veterinary use; cell culture media for scientific and research purposes
Class 5
Pharmaceutical products for treatment of cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; medicinal preparations for disease treatmentfor preventing or treating cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; preparations for medical treatmentsin particular preparations based on polypeptides and proteins for treatment of cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; protein complexes for diagnosing cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; synthetic peptides for pharmaceutical usefor treatment of cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; diagnostic agentspreparations and substances for medical purposes; diagnostic substances for medical use; medicinal preparations and substances for preventing and treating cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; pharmaceutical preparations and substances for preventing and treating cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; agents and medicines for therapeutic usefor the treatment of cancerautoimmune diseasesinflammatory disordersdiseases in the fields of oncology and immunology; cells for medical use; chemicalbiochemical and biological preparations being biologicalbiochemicalimmunological pharmaceutical preparations for medical use
Class 42
Analysis and research in laboratories being research laboratory analysis services in the field of chemistrybiochemistrymolecular biology; scientific research and analysis in the field of chemistrybiochemistrymolecular biologyimmunology; cell culture for scientific research purposesfor others; design and development of medical technologies; research and development in the field of biotechnology; research and development in the field of microorganisms and cells; research and development in the field of diagnostic preparations; pharmaceutical research and development; biochemical research and development; scientific and technological researchparticularly in the biochemicaldiagnostic or pharmaceutical fields; research and development for the pharmaceutical industry; research and development services in the field of proteinsmicroorganisms and cells; research and development services in the field of immunology; services of a chemicalbiochemical and biological research laboratory; research servicesanalyses in the field of molecular biology
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/19/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/31/2026
PUBO
PUBLISHED FOR OPPOSITION
03/31/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/25/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/10/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/09/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/09/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/09/2026
RFNT
REFUSAL PROCESSED BY IB
02/12/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/24/2026
RFRR
REFUSAL PROCESSED BY MPU
01/24/2026
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/15/2025
CNRT
NON-FINAL ACTION WRITTEN
12/14/2025
DOCK
ASSIGNED TO EXAMINER
12/12/2025
MAFR
APPLICATION FILING RECEIPT MAILED
10/27/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/27/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/23/2025
Continuous trademark protection
Get notified about every new filing that threatens MABQUEST THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.